Douglas Ingram

2017

In 2017, Douglas Ingram earned a total compensation of $56.9M as President and Chief Executive Officer at Sarepta Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$420,875
Option Awards$44,484,000
Salary$337,500
Stock Awards$11,607,750
Other$16,116
Total$56,866,241

Ingram received $44.5M in option awards, accounting for 78.23% of the total pay in 2017.

Ingram also received $420.9K in non-equity incentive plan, $337.5K in salary, $11.6M in stock awards and $16.1K in other compensation.

Rankings

In 2017, Douglas Ingram's compensation ranked 20th out of 14,030 executives tracked by ExecPay. In other words, Ingram earned more than 99.9% of executives.

ClassificationRankingPercentile
All
20
out of 14,030
100th
Division
Manufacturing
4
out of 5,558
100th
Major group
Chemicals And Allied Products
1
out of 1,968
100th
Industry group
Drugs
1
out of 1,632
100th
Industry
Pharmaceutical Preparations
1
out of 1,256
100th
Source: SEC filing on April 26, 2018.

Ingram's colleagues

We found six more compensation records of executives who worked with Douglas Ingram at Sarepta Therapeutics in 2017.

2017

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2017

Guriqbal Basi

Sarepta Therapeutics

Chief Scientific Officer

2017

Alexander Cumbo

Sarepta Therapeutics

Senior Vice President, Chief Commercial Officer

2017

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2017

David Howton

Sarepta Therapeutics

General Counsel

2017

Catherine Stehman-Breen

Sarepta Therapeutics

Chief Medical Officer

News

In-depth

You may also like